6:04 PM
 | 
Aug 29, 2012
 |  BC Extra  |  Clinical News

Lilly drops mGluR2/3 agonist after schizophrenia misses

Eli Lilly and Co. (NYSE:LLY) discontinued development of pomaglumetad methionil after a futility analysis showed that the compound was unlikely to be effective against placebo in the second of two pivotal trials in schizophrenia. The...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >